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Abstract 
The bifunctional chelator NODIA-Me holds promise for radiopharmaceutical development. 
NODIA-Me is based on the macrocycle TACN (1,4,7-triazacyclononane) and incorporates two 
additional methylimidazole arms for metal chelation and an acetic acid residue for bioconjugation. 
The original two step synthesis was less than optimal due to low yields and the requirement of 
semi-preparative RP-HPLC purifications. Here, the overall yield for the preparation of NODIA-
Me was improved two- to five-fold via two synthetic routes using different protection/deprotection 
techniques. This way, it was possible (1) to prepare of NODIA-Me on multi-gram scale and (2) to 
avoid time-consuming HPLC purifications. 
 Inspired by recent results with nat/68Ga3+, preliminary studies on the radiolabeling properties 
and complex formation of NODIA-Me with nat/111In3+ were performed. Quantitative radiochemical 
yields were achieved at ambient temperature providing molar activities of ~30 MBq nmol-1, which 
could be increased to ~240 MBq nmol-1 at 95 °C. At r.t., pH 5.5 was optimal for 111In-labeling, but 
quantitative yields were also achieved in the pH range from 5.5 to 8.2, when the reaction 
temperature was increased. Stability tests of 111In complexes in vitro revealed high kinetic 
stabilities in serum and ligand challenge experiments, which is a consequence of the formation of 
rigid 1:1 indium chelates as shown by NMR studies in solution. In summary, the new synthetic 
routes afford the BFC NODIA-Me in high yields and on large scale. Further, 111In complexation 
experiments broaden the scope of our chelating system for radiopharmaceutical applications.  
 
 
Key words: NODIA-Me, bifunctional chelator (BFC), Indium-111, prostate-specific membrane 
antigen (PSMA), single-photon emission computed tomography (SPECT). 
 Page 3 
 
Introduction 
The majority of radiopharmaceuticals used in nuclear medicine for imaging and therapy are labeled 
with radioactive metal isotopes. Because of this, targeted radiopharmaceuticals generally comprise 
a target-specific vector molecule, which carries the radioactivity to the site(s) of interest, and a 
metal-binding part, a so-called bifunctional chelator (BFC), that (1) is covalently attached to the 
targeting biomolecule and (2) strongly binds the radiometal ion. However, introduction of a metal 
chelate is a non-innocent modification that often affects the pharmacological properties of the 
entire bioconjugate.1, 2 On the other hand, the dependency of the radiotracer’s performance on the 
chemical structure of the metal chelate also presents an opportunity for chemists to tune the 
pharmacokinetics of a particular radiopharmaceutical. Tailored chelator design provides control 
over the metal complex properties such as labeling efficiency and stability but, more importantly, 
also over the overall charge, lipophilicity and size, thereby serving as valuable tool for radiotracer 
optimization with regards to target specificity and pharmacokinetics in vivo. The important role 
that the chemical nature of the metal chelate has on the biological performance of targeted 
radiopharmaceuticals demands continued development and optimization of new BFCs. 
 We recently developed a chelating system based on the macrocycle TACN (1,4,7-
triazacyclononane) that incorporates two or three additional azaheterocycles to provide either a 
penta- or hexadentate coordination geometry for metal binding. Initial studies focused on the triply 
substituted compounds NOTI (1,4,7-tris((1H-imidazol-2-yl)methyl)-1,4,7-triazonane), NOTI-Me 
(1,4,7-tris((1-methyl-1H-imidazol-2-yl)methyl)-1,4,7-triazonane) and NOTThia (1,4,7-
tris(thiazol-2-ylmethyl)-1,4,7-triazonane).3 These chelators exhibited excellent complexation 
properties for the positron- and beta-emitting nuclide 64Cu2+, which are a consequence of the 
pronounced affinity of the borderline Cu2+ cation (according to Pearson’s hard and soft acids and 
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bases HSAB principle) to the azaheterocyclic N donors. These findings were also corroborated by 
Tripier and co-workers, who investigated the complex formation of the TACN based ligand no2th 
bearing two methylthiazolyl arms with Cu2+ and found that the corresponding Cu(II)(no2th) complex 
was of high thermodynamic and kinetic stability.4 Moreover, we showed that TACN derived ligands 
bearing additional methylimidazole arms can be used for stable complexation of the PET isotope 
68Ga3+.5  
More recently, the bifunctional derivative NODIA-Me (2-(4,7-bis((1-methyl-1H-imidazol-
2-yl)methyl)-1,4,7-triazonan-1-yl)acetic acid) was described, which incorporates an acetic acid 
group for the covalent attachment of targeting vectors. The applicability of NODIA-Me for the 
development of 68Ga- and 64Cu-labeled radiopharmaceuticals was subsequently demonstrated by 
conjugation to a prostate-specific membrane antigen (PSMA) targeting vector.5 Small-animal PET 
imaging and ex vivo biodistribution studies of corresponding 68Ga- and 64Cu-labeled NODIA-Me-
NaI-Ahx-PSMA conjugates showed specific accumulation in PSMA-positive LNCaP tumors.6 
Both compounds exhibited rapid renal clearance with low uptake in non-target tissues confirming 
sufficient stability of 68Ga- and 64Cu(NODIA-Me) chelates in vivo. Furthermore, NODIA-Me was 
recently coupled to the peptide c(RGDfK) for targeting the integrin avß3 receptor.6 The 
corresponding 68Ga-labeled radiotracer showed low uptake in non-target organs and specific 
uptake in U-87 MG tumor xenografts in athymic mice, which were clearly visualized by PET.  
 The initial synthesis of NODIA-Me, however, was suboptimal due to low yields and the 
need for time-consuming RP-HPLC purifications. Even though NODIA-Me could be obtained in 
only two reaction steps, the overall yield was only about 20%, and thus, too low for multi-gram 
scale syntheses. Obviously, these drawbacks demanded optimization of the preparation, which we 
addressed in the present study. 
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 An ideal BFC should be versatile in terms of complexation to allow its use in combination 
with various radiometals for different applications. Since our imidazole-type ligands showed 
excellent complexation properties with the semimetal nat/68Ga, we were also interested in the 
complex formation of NODIA-Me with the group 13 congener 111In as this might further expand 
the applicability of our chelating system. The radionuclide 111In decays with a half-life of 2.8 d by 
electron capture emitting two gamma rays at 171 keV and 245 keV and is widely used in clinics 
for diagnostic imaging by SPECT or planar scintigraphy. For example, 111In-labeled compounds 
include antibodies for prostate cancer imaging (ProstaScintâ), In(DTPA) for cerebrospinal fluid 
imaging, In(oxyquinoline) for labeling of white blood cells and In(pentetreotide) for imaging of 
neuroendocrine tumors (Octreoscanâ).7-11 For information about the coordination chemistry of 
indium and ligands used for 111In-labeled radiopharmaceuticals the readers are referred to more 
specialized review articles.12, 13  
 
Experimental 
General 
Chemicals and solvents of the highest grade commercially available were purchased from Sigma-
Aldrich and TCI Europe, and used as received. The precursor Glu-CO-Lys(Ahx)-(tBu)3 ester was 
purchased from ABX (Radeberg, Germany) and the macrocycle TACN (1,4,7-triazacyclonane) 
was obtained from Chematech (Dijon, France). No carrier added [111In]InCl3 in 0.02 M 
hydrochloric acid was purchased from Mallinckrodt Pharmaceuticals (Petten, The Netherlands). 
The bioconjugate NODIA-Me-NaI-Ahx-Lys-CO-Glu (NODIA-Me-NaI-Ahx-PSMA) was 
prepared as previously described.5, 6 NMR spectra were recorded on a Bruker Avance II WB (1H 
400 MHz, 13C 101 MHz, 14N 29 MHz, 15N 41 MHz), a Bruker Avance III HD (1H 300 MHz, 13C 
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75 MHz, 14N 22 MHz, 15N 30MHz) or a Bruker DPX (1H 200 MHz, 13C 50 MHz) at 298 K. 
Solvents were CDCl3 or D2O. Spectra were calibrated on solvent signals (7.260 ppm for CDCl3, 
4.790 ppm for D2O).14 Chemical shifts are given in parts per million (ppm) and are reported relative 
to trimethylsilane (TMS). Coupling constants are reported in hertz (Hz). The multiplicity of the 
NMR signals is described as follows: s = singlet, d = duplet, t = triplet, q = quartet, m = multiplet. 
High resolution mass spectrometry ((+)-HR-ESI-MS) was performed on a Thermo Scientific 
Exactive mass spectrometer. Reversed-phase high performance liquid chromatography (RP-
HPLC) was conducted on an Agilent 1260 Infinity System equipped with an Agilent 1200 DAD 
UV detector (UV detection at 220 nm) and a Raytest Ramona radiation detector (Raytest GmbH, 
Straubenhardt, Germany) in series. A Phenomenex Jupiter Proteo (250 x 4.60 mm) column was 
used for analytical HPLC. The solvent system was A = H2O (0.1% TFA) and B = acetonitrile 
(0.1% TFA). The gradient was 0-1 min at 5% B, 1-25 min 5-50% B at a flow rate of 1 mL min-1. 
Semi-preparative RP-HPLC was performed on a Knauer Smartline 1000 HPLC system in 
combination with a Macherey Nagel VP 250/21 Nucleosil 120-5 C18 column. Conditions were 0-
40 min 5-60% B at a flow rate of 12 mL min-1. Samples were lyophilized using a Christ Alpha 1-
2 LD plus lyophilizer. For automated reversed-phase flash chromatography, a Biotage Isolera 
Four in combination with a SNAP Ultra C18 column (30g) was used. The solvent system was A = 
H2O (0.1% TFA) and B = acetonitrile (0.1% TFA). UV detection was set to 220 nm and 240 nm. 
The gradient used was 0 – 30 mL 0% B, 30 – 120 mL 0-100% B, 120 – 150 mL 100% B at a flow 
rate of 25 mL min-1. Radioactivity measurements were made by using an Activimeter ISOMED 
2010 (Nuklear-Medizintechnik, Dresden, Germany). For accurate quantification of radioactivity, 
experimental samples were counted for 1 min on a calibrated Perkin Elmer (Waltham, MA) 2480 
Automatic Wizard Gamma Counter by using a dynamic energy window of 171 and 245 keV for 
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111In. Radio-TLC strips were analyzed on a Cyclone Plus Storage Phosphor Scanner 
(PerkinElmer). All instruments measuring radioactivity were calibrated and maintained in 
accordance with previously reported routine quality-control procedures.15 A ThermoFisher 
Heraeus Fresco 21 centrifuge was used for centrifugation. IR spectra were recorded on a Nicolet 
iS 10 FT-IR-spectrometer equipped with an ATR unit from ThermoFisher Scientific. Band 
intensities are described as follows: w = weak, m = medium, s = strong. Elemental analysis was 
performed using a Vario MICRO cube from Elementar Analysensysteme GmbH. 
 Synthetic procedures and characterization data of the model compound NODIA-Me-NH-
Et (12) as well as the metal complexes In-12 and In-13 are given in the Supporting Information. 
 
Ligand Syntheses  
1,4,7-Tritosyl-1,4,7-triazanonane (1) 
Caesium carbonate (9.12 g, 28.0 mmol), dried under vacuum for 1 h at 60 °C, was mixed with 
N,N‘,N‘‘-tritosyldiethylenetriamine (7.35 g, 13.0 mmol) in dry DMF (80 mL) under argon and 
allowed to stir for 1.5 h at r.t. (room temperature). To this suspension, a solution of 1,2-
bis(tosyloxy)ethane (4.82 g, 13.0 mmol) in dry DMF (30 mL) was added dropwise over 1 h. 
Stirring was continued for additional 2 d at r.t. The reaction mixture was then poured into water 
(400 mL) under vigorous stirring resulting in the formation of a colorless precipitate, which was 
filtered off and dried under vacuum. The colorless solid was suspended in DMF/water (1:1, v/v, 
200 mL) and stirred overnight. The crude product was filtered, washed with water (5 x 50 mL), 
dissolved in dichloromethane and filtered over CeliteÒ. The solvent was removed and the residue 
taken up in a small volume of dichloromethane (~20 mL). Slow addition of dry ethanol (100 mL) 
resulted in crystallization of the product. After cooling to 0 °C, crystals were filtered off and dried 
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under vacuum to give 1 as colorless, crystalline powder (7.40 g, 96%). 1H NMR (300 MHz, 
CDCl3): d = 7.70 (m, 6H, tosyl), 7.32 (m, 6H, tosyl), 3.42 (s, 12H, macrocycle), 2.43 (s, 9H, tosyl-
Me) ppm; 13C NMR (75 MHz, CDCl3): d = 144.0 (tosyl), 134.7 (tosyl), 130.0 (tosyl), 127.6 (tosyl), 
52.0 (macrocycle), 21.7 (tosyl-Me) ppm. HR-ESI-MS calcd m/z for C27H33N3O6S3Na+: 614.1423, 
found: 614.1421. IR (ATR) ν = 3072 (w), 2924 (w), 2851 (w), 1342 (m), 1326 (m), 1154 (s), 1087 
(m), 980 (m), 926 (m), 821 (m), 810 (m), 709 (m), 688 (s), 639 (m), 544 (s) cm-1. 
 
1-Tosyl-1,4,7-triazanonane (2) 
1,4,7-Tritosyl-1,4,7-triazonane 1 (7.80 g, 13.18 mmol) and phenol (9.41 g, 100.00 mmol) were 
suspended in a solution of HBr in AcOH (30%, 110 mL) under argon. Caution: during the reaction 
corrosive vapors are released. The mixture was carefully heated to 90 °C for 1 h (Caution: gas 
evolution begins between 60-70 °C), while the reactants completely dissolved. Heating was 
continued at 90 °C for additional 3 d during which a white precipitate formed (precipitation started 
after about 2 – 3 h). The reaction mixture was cooled to r.t. and allowed to sit overnight. The 
formed precipitate was filtered off and washed with diethylether (3 x 20 mL). To this residue, 1.5 
M sodium hydroxide was added until complete dissolution (pink solution). The product was 
extracted from the aqueous phase with chloroform (4 x 15 mL), filtered over CeliteÒ and the 
solvent removed by rotary evaporation. After drying of the product under high vacuum, compound 
2 was obtained as a yellowish solid (2.92 g, 78%). 1H NMR (300 MHz, CDCl3): d = 7.68 (m, 2H, 
tosyl), 7.29 (m, 2H, tosyl), 3.17 (m, 4H, macrocycle), 3.07 (m, 4H, macrocycle), 2.88 (s, 4H, 
macrocycle), 2.41 (s, 3H, tosyl-Me), 1.74 (s, 2H, NH) ppm. 13C NMR (101 MHz, CDCl3): δ = 
143.3 (tosyl), 135.7 (tosyl), 129.8 (tosyl), 127.4 (tosyl), 54.2 (macrocycle), 49.8 (macrocycle), 
49.7 (macrocycle), 21.6 (tosyl-Me) ppm. HR-ESI-MS calcd m/z for C13H22N3O2S+: 284.1427, 
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found: 284.1430. IR (ATR) ν = 2976 (w), 2946 (w), 2209 (w), 2190 (m), 1717 (w), 1691 (w), 1479 
(m), 1450 (m), 1390 (m), 1323 (w), 1230 (m), 1170 (m), 1147 (m), 1112 (w), 998 (m), 921 (s), 
782 (m), 685 (m) cm-1. 
 
1-((1-Methyl-1H-imidazol-2-yl)methyl)-4-((1-methyl-4,5-dihydro-1H-imidazol-2-yl)methyl)-7-
tosyl-1,4,7-triazanonane (3) 
Compound 2 (0.51 g, 1.79 mmol) and 1-methyl-2-imidazolecarboxaldehyde (0.44 g, 4.00 mmol) 
were dissolved in dry THF (8 mL) under argon. The reaction mixture was stirred at r.t. for 25 h 
during which a yellow solution formed. Then, sodium triacetoxyborohydride (0.46 g, 2.16 mmol) 
was added in small portions and the resulting suspension stirred for additional 5 h. More sodium 
triatectoxyborohydride (0.45 g, 2.12 mmol) was added in small portions and stirring continued for 
another 18 h. The reaction was quenched using aqueous hydrochloric acid (1 M, 10 mL) and stirred 
for additional 30 min. The pH was adjusted to >10 with 40% sodium hydroxide solution resulting 
in formation of a white precipitate. The aqueous phase was extracted with chloroform (4 x 5 mL) 
and the combined organic layers washed with water (3 x 10 mL) and brine (10 mL), and dried 
using anhydrous sodium sulfate. The solvent was removed and the residue taken up in an 
acetonitrile/water mixture (90:10, 10 mL, both 0.1% TFA). The crude product was further purified 
by automated flash chromatography. Fractions containing the product were combined, the pH 
adjusted to pH >10 with aqueous sodium hydroxide solution (10%, ~5 mL) and extracted with 
chloroform (4 x 10 mL). The chloroform phase was dried with anhydrous sodium sulfate, filtered 
and the solvent removed under vacuum. After drying under high vacuum, compound 3 was 
obtained as colorless resin (0.82 g, 98%). 1H NMR (300 MHz, CDCl3): d = 7.56 (m, 2H, tosyl), 
7.25 (m, 2H, tosyl), 6.89 (d, J = 1.2 Hz, 2H, imidazole), 6.82 (d, J = 1.2 Hz, 2H, imidazole), 3.71 
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(s, 4H, CH2), 3.69 (s, 6H, imidazol-Me), 3.01 (m, 4H, macrocycle), 2.93 (m, 4H, macrocycle), 
2.73 (s, 4H, macrocycle), 2.39 (s, 3H, tosyl-Me) ppm. 13C NMR (75 MHz, CDCl3): δ = 145.7 
(imidazole), 143.2 (tosyl), 135.5 (tosyl), 129.7 (tosyl), 127.3 (br, tosyl, imidazol), 121.6 
(imidazole-CH), 56.4 (macrocycle), 55.0 (macrocycle), 54.5 (CH2), 51.1 (macrocycle), 33.1 
(imidazole-Me), 21.6 (tosyl-Me) ppm. HR-ESI-MS calcd m/z for C23H34N7O2S+: 472.2489, found: 
472.2488. IR (ATR) ν = 2924 (w), 2825 (w), 1498 (m), 1449 (m), 1332 (m), 1283 (m), 1154 (s), 
1089 (m), 973 (m), 921 (m), 815 (m), 746 (s), 710 (m), 693 (s), 664 (m), 641 (m), 566 (m), 547 
(s) cm-1. 
 
1-((1-Methyl-1H-imidazol-2-yl)methyl)-4-((1-methyl-4,5-dihydro-1H-imidazol-2-yl)methyl)-
1,4,7-triazanonane NODI-Me (4) 
Removal of the tosyl protecting group was accomplished by heating compound 3 (0.81 g, 1.71 
mmol) in concentrated sulfuric acid (15 mL) under argon for 48 h at 110 °C. After cooling to r.t., 
the reaction mixture was added carefully to ice. The resulting solution was neutralized with sodium 
hydroxide solution (10%) and the solvent removed by rotary evaporation. The crude product was 
further purified by automated flash chromatography to give NODI-Me (4) × 5 TFA as colorless oil 
(0.52 g, 34%).1H NMR (400 MHz, D2O, pD < 2): d = 7.42 (d, J = 2.1 Hz, 2H, imidazole), 7.41 (d, 
J = 2.1 Hz, 2H, imidazole), 4.16 (s, 4H, CH2), 3.82 (s, 6H, imidazole-Me), 3.25 (t, J = 5.8 Hz, 4H, 
macrocycle), 3.01 (t, J = 5.8 Hz, 4H, macrocycle), 2.65 (s, 4H, macrocycle) ppm. 13C NMR (75 
MHz, D2O, pD < 2): δ = 143.4 (imidazole), 124.4 (imidazole-CH), 119.0 (imidazole-CH), 50.6 
(macrocycle), 48.5 (CH2), 47.6 (macrocycle), 43.9 (macrocycle), 34.7 (imidazole-Me) ppm. 15N 
NMR (30 MHz, D2O, pD < 2): δ = -208 (imidazole), -210 (imidazole-Me), -356 (macrocycle-NH), 
-349 (macrocycle) ppm. HR-ESI-MS calcd m/z for C16H28N7+: 318.2401, found: 318.2404. IR 
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(ATR) ν = 2854 (w), 1739 (m), 1669 (s), 1606 (m), 1531 (m), 1461 (m), 1405 (m), 1278 (m), 1128 
(s), 1021 (m), 920 (m), 796 (s), 751 (m), 720 (s), 704 (s), 593 (m) cm-1. Elemental analysis calc. 
C: 35.18%, H: 3.63%, N: 11.05%, found C: 35.75 %, H: 3.99%, N: 10.83%. 
 
Di-tert-butyl (1,4,7-triazanonane-1,4-diyl) bis(carbonate) (5) 
To a solution of TACN (3.16 g, 24.47 mmol) in chloroform (80 mL) was added portion-wise BOC-
ON (2-(Boc-oxyimino)-2-phenylacetonitrile) (11.98 g, 48.63 mmol) and the mixture was stirred 
for 3 d at r.t. The solvent was removed and the residue taken up in aqueous sodium hydroxide 
solution (10%, 32 mL) and diethylether (95 mL). The organic layer was washed with aqueous 
sodium hydroxide solution (10%, 3 x 16 mL) and water (3 x 16 mL), dried using anhydrous sodium 
sulfate, filtered and the solvent removed by rotary evaporation. The crude product was purified by 
silica gel column chromatography (petrol ether/ethylacetate 2:3 followed by ethanol with 1% 
triethylamine). Fractions containing the product were combined and the solvent removed to give 
compound 5 as yellow oil (7.10 g, 88%). Several isomers were observed in the NMR 
measurements. 1H NMR (400 MHz, CDCl3): d = 3.45 (m, 4H, macrocycle), 3.25 (m, 4H, 
macrocycle), 2.92 (m, 4H, macrocycle), 2.23 (s, 1H, NH), 1.47 (s, 18H, tBu) ppm. 13C NMR (50 
MHz, CDCl3): δ = 156.2, 155.9 (carbonyl), 80.0, 79.9 (tBu), 53.1, 52.5, 52.4, 51.6, 50.6, 50.5, 
49.9, 49.7, 48.2, 48.1, 47.7, 47.3 (macrocycle), 28.7 (br, tBu-CH3) ppm. HR-ESI-MS calcd m/z 
for C16H32N3O4+: 330.2387, found: 330.2388. IR (ATR) ν = 2974 (w), 2930 (w), 1684 (s), 1461 
(m), 1409 (s), 1364 (s), 1245 (s), 1165 (s), 1130 (s), 1071 (w), 1033 (w), 980 (m), 860 (m), 771 
(m), 755 (m), 665 (w), 617 (w) cm-1. Rf value (silica plates): 0.05 (PE/EA 2:3), 0.57 (ethanol + 
1% Et3N). 
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Ethyl 2-(4,7-bis((tert-butoxycarbonyl)oxy)-1,4,7-triazanonan-1-yl)acetate (6) 
Compound 5 (0.71 g, 2.16 mmol) and potassium carbonate (1.19 g, 8.62 mmol) were suspended 
in dry acetonitrile (21.5 mL) under argon. Ethylbromoacetate (0.24 mL, 2.16 mmol) was added 
dropwise und the mixture was then stirred for 18 h under reflux. The solvent was removed and the 
residue dissolved in saturated sodium carbonate solution (30 mL). The aqueous phase was 
extracted with chloroform (3 x 15 mL), the combined organic layers dried using anhydrous sodium 
sulfate, filtered and the solvent was removed once more by rotary evaporation. The crude product 
was purified by silica gel column chromatography (petroleum ether/ethylacetate 3:1). Fractions 
containing the product were combined and the solvent removed to give compound 6 as colorless 
oil (0.82 g, 91%). Several isomers were observed in the NMR measurements. 1H NMR (400 MHz, 
CDCl3): d = 4.15 (m, 2H, ethyl-CH2), 3.45 (m, 4H, macrocycle), 3.42 (s, 2H, CH2), 3.24 (m, 4H, 
macrocycle), 2.83 (m, 4H, macrocycle), 1.46 (s, 18H, tBu), 1.26 (m, 3H, ethyl-CH3) ppm. 13C 
NMR (101 MHz, CDCl3): δ = 172.2 (br), 172.2, 172.2 (AcOEt-carbonyl), 155.8 (br), 155.8, 155.6 
(BOC-carbonyl), 79.6, 79.6, 79.5, 79.5 (tBu), 60.5, 60.4, 60.3, 60.3 (ethyl-CH2), 56.4(br, CH2), 
54.5, 53.9, 53.9, 53.7 51.2, 51.0, 50.9, 50.6, 50.3, 50.0, 49.8, 49.6 (macrocycle), 28.7, 28.7 (tBu-
CH3), 14.5, 14.4 (ethyl-CH3) ppm. HR-ESI-MS calcd m/z for C20H38N3O6+: 416.2755, found: 
416.2751. IR (ATR) ν = 2975 (w), 2932 (w), 1741 (m), 1686 (s), 1460 (m), 1411 (m), 1365 (m), 
1248 (m), 1154 (s), 1098 (m), 1030 (m), 1000 (w), 967 (m), 859 (w), 754 (m) cm-1. Rf value (silica 
plates): 0.42 (PE/EA 3:1). 
 
Ethyl 2-(1,4,7-triazanonan-1-yl)acetate (7) 
Compound 6 (2.21 g, 5.32 mmol) was dissolved in CH2Cl2 (6 mL). The solution was cooled with 
ice and TFA (6 mL) was added dropwise. The reaction mixture was stirred for 2.5 h at r.t. Then, 
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the solvent was removed. The resulting residue was dissolved in a few drops of water and 
lyophilized to give the TFA salt of compound 7 × 3 TFA× 4 H2O as a yellow oil (3.32 g, quant.). 
1H-NMR (300 MHz, D2O, pD < 2) δ = 4.19 (q, J = 7.2 Hz, 2H, ethyl-CH2), 3.65 (s, 4H, 
macrocycle), 3.61 (s, 2H, CH2), 3.31 (m, 4H, macrocycle), 3.09 (m, 4H, macrocycle), 1.23 (t, J = 
7.2 Hz, 3H, ethyl-CH3) ppm. 13C-NMR (50 MHz, D2O, pD < 2) δ = 173.9 (carbonyl), 62.3 (ethyl-
CH2), 55.1 (CH2), 48.5 (macrocycle), 43.9 (macrocycle), 42.6 (macrocycle), 13.2 (ethyl-CH3) 
ppm. 15N-NMR (30 MHz, D2O, pD < 2) δ = -345 (macrocycle-NH), -363 (macrocycle-AcOEt) 
ppm. HR-ESI-MS calcd m/z for C10H22N3O2+: 216.1707, found: 216.1704. IR (ATR) ν = 3405 (br, 
w), 1669 (m), 1435 (w), 1385 (w), 1139 (s), 1029 (m), 941 (w), 841 (m), 799 (m), 783 (m), 723 
(m), 704 (m), 598 (m) cm-1. Elemental analysis calc. C: 30.53%, H: 5.12%, N: 6.68%, found C: 
31.70%, H: 4.49%, N: 6.61%. 
 
2-(4-((1-Methyl-1H-imidazol-2-yl)methyl)-7-((1-methyl-4,5-dihydro-1H-imidazol-2-yl)methyl)-
1,4,7-triazanonan-1-yl)acetic acid NODIA-Me (8)  
Route A: 
Introduction of the acetic acid arm to give the BFC NODIA-Me 8 was performed as previously 
reported with a yield of 90%. Characterization was consistent with previously reported data.5 
Route B: 
Compound 7 (2.92 g, 4.65 mmol), 1-methyl- 2-imidazolcarboxaldehyde (1.66 g, 15.08 mmol) and 
DIPEA (5 mL, 30 mmol) were dissolved in dry THF under argon and heated at 50 °C for 14 h. 
After cooling to r.t., sodium triacetoxyborohydride (1.53 g, 7.20 mmol) was added in portions and 
the suspension stirred for 3 h. Then, additional sodium triacetoxyborohydride (1.79 g, 8.44 mmol) 
was added and stirring continued for additional 3 h. The solvent was removed, the residue taken 
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up in H2O/MeCN (0.1% TFA) and purified by flash chromatography. Fractions containing the 
product were combined and the solvents removed. For hydrolysis of the ester, the residue was 
refluxed in hydrochloric acid (6 M, 50 mL) for 5 days. After removal of the solvent, the BFC 
NODIA-Me 8 was obtained as orange oil (2.19 g, 85%). NMR characterization was identical to 
previously reported NMR data.5 HR-ESI-MS calcd m/z for C18H30N7O2+: 376.2461, found: 
376.2459.  
 
Radiolabeling Experiments 
111In labelling experiments for NODIA-Me-NH-Et ([111In]In-12) 
An 1 µM stock solution of 12 in the corresponding buffer solution was prepared. For labelling 
experiments, 33 µL of this stock solution were mixed with 46.5 µL of the corresponding buffer 
solution (all 0.1 M; NaOAc pH 4.0, NaOAc pH 4.5, NaOAc pH 5.5, MES pH 5.5, HEPES pH 7.4 
and NH4OAc pH 8.2). To these solutions, 1-2 MBq [111In]InCl3 (3 µL) were added to give a total 
volume of 82.5 µL and a final ligand concentration of 0.4 µM. Reactions were incubated for 15 
min at either r.t. or 95 °C. Radiochemical conversion (RCC) was checked by TLC using silica gel 
microfiber strips (Agilent, iTLC-SG glass microfiber) and DTPA solution (50 mM, pH 7.4). Strips 
were analyzed by phosphorimaging. For the dilution series, either 16.5, 8.25 or 4.12 µL of ligand 
stock solution were added to 63, 71.25 or 75.37 µL of ammonium acetate buffer followed by the 
addition of 1-2 MBq [111In]InCl3 (3 µL). Samples were again incubated for 15 min either at r.t. or 
95 °C and the RCC checked by TLC. Each experiment was performed in triplicate. Rf ([111In]In-
12) = 0-0.1, Rf ([111In]In-DTPA) = 0.9-1.0.     
 
111In labelling experiments for NODIA-Me-NaI-Ahx-PSMA ([111In]In-13) 
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An aliquot of a stock solution of the bioconjugate 13 (2 µg µL-1) in water was 1000-fold diluted 
in the corresponding labelling buffer (all 0.1 M; NaOAc pH 4.0, NaOAc pH 4.5, NaOAc pH 5.5, 
MES pH 5.5, HEPES pH 7.4, HEPES pH 8.2 and NH4OAc pH 8.2) followed by the addition of 
~1-2 MBq [111In]InCl3. In a typical labelling experiment, 17 µL (~0.033 nmol) of the diluted stock 
solution of 13 were added to 75 µL labelling buffer followed by 8 µL (~1-2 MBq) [111In]InCl3. 
After brief mixing, samples were either incubated at r.t. or 95 °C for 15 minutes. Analysis was 
initially performed by analytical RP-HPLC and the RCC was determined as described for 12. No 
differences between the HPLC and TLC analyzed samples were observed so that determination 
was continued by TLC. Each experiment was performed at least in triplicate. Rf ([111In]In-13) = 0-
0.1, Rf ([111In]In-DTPA) = 0.9-1.0. RP-HPLC (analytical, radioactivity detector): tR ([111In]In-13) 
= 17:46 min. 
 
In Vitro Characterization  
Lipophilicity (log Doct/PBS) measurements 
For the determination of the partition coefficient, ~0.4 MBq of [111In]In-13 in saline (20 µL) was 
added to a pre-saturated mixture of phosphate buffered saline pH 7.4 (PBS) (480 µL) and n-octanol 
(500 µL). Samples were shaken for 1 h at r.t. For separation, the samples were centrifuged at 
21,100 g for 5 min. From each phase, 50 µL were transferred into counting tubes, and samples 
were counted using a Perkin Elmer gamma counter. The experiment was performed in triplicate. 
 
DTPA challenge experiments  
0.2-0.4 MBq (10 µL) of [111In]In-13 were added into 200 µL of DTPA (diethylenetriamine penta-
acetic acid) (50 mM, pH 7.4) and stored at r.t. At selected time points, 20 µL samples were drawn 
 Page 16 
 
and analyzed by analytical RP-HPLC. The percentage of intact 111In-13 was calculated from the 
HPLC chromatograms. The experiment was performed in triplicate. 
 
Serum stability measurements 
0.5–1 MBq (50 µL) of [111In]In-13 were added to human serum (1 mL, human male AB plasma, 
Sigma-Aldrich), which was pre-equilibrated at 37 °C in a cell incubator for 1 h. Samples were 
vortexed and stored at 37 °C. At selected time points, 100 µL aliquots were taken and serum 
proteins were removed by centrifugation (4,000 g for 5 min at 4 °C) using molecular weight cutoff 
filter tubes (30 kDa). The filter was then washed twice with 100 µL PBS with additional 
centrifugation steps. For determination of protein bound fraction, the filters and the filtrates were 
transferred into counting tubes, and samples were measured using a Perkin Elmer gamma counter. 
A sample of the filtrate was kept on ice until HPLC analysis. The percentage of intact 111In-13 was 
calculated from the HPLC chromatograms. The experiment was performed in triplicate. 
 
Competitive binding assay 
PSMA-positive LNCaP cells (ATCC, Manassas, VA, USA) were cultured at 37 °C under a 5% 
CO2 atmosphere (RPMI Medium 1640 GlutaMAX containing 10% FBS, 1% 100 U mL-1 penicillin 
and 100 µg mL-1 streptomycin, 1% sodium-pyruvate 1 mM, 1% L-glutamin 2 mM). The binding 
affinity of the bioconjugate 13 and the corresponding In-13 was determined using a cell-based 
competitive binding assay with 68Ga-labelled PSMA-HBED-CC (DKFZ-PSMA-11) according to 
the literature with minor modifications.16 Briefly, each compound at different concentrations (0 – 
10,000 nM) was incubated for 1 h at 37 °C with 0.15 nM [68Ga]Ga-PSMA-HBED-CC together 
with 2×105 LNCaP cells per well. After incubation, cells were washed three times with ice-cold 
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PBS and cell-associated activity recovered by addition of 1 M NaOH. Radioactivity was measured 
by a Perkin Elmer gamma counter and data fitted using non-linear regression (GraphPad Prism). 
Experiments were performed two times in triplicate. 
 
Results and Discussion 
Ligand Syntheses 
In order to improve the overall yield for the synthesis of NODIA-Me and to avoid the cumbersome 
purification by semi-preparative RP-HPLC, two synthetic strategies using different protecting 
group techniques were investigated (Scheme 1). Route A starts with the commercially available 
and cost-effective starting materials N,N‘,N‘‘-tritosyldiethylenetriamine and 1,2-
bis(tosyloxy)ethane enabling the simultaneous build-up and protection of the TACN ring in 96% 
yield (Scheme 1A).17 The triply tosyl-protected TACN derivative 1 was then selectively 
deprotected in a HBr/AcOH mixture to give the single-protected compound 2 in 78% yield. The 
mono-protected TACN 2 is not soluble in the reaction mixture and precipitates with progression 
of the reaction. The intermediate 2 was consequently isolated by filtration. Introduction of the 
methylimidazole residues was accomplished by reductive amination with minor modifications to 
reported methods producing the intermediate 3 in an almost quantitative yield of 98%.3 NODI-Me 
4 was obtained in 34% yield after removal of the final tosyl protecting group by refluxing 
compound 3 in concentrated sulfuric acid for 48 h. We did not attempt to optimize the conditions 
of this deprotection step because in spite of these harsh reaction conditions, the overall yield for 
NODI-Me was approximately doubled (25% vs. 14%) through the use of this protection-
deprotection approach, thereby eliminating the need for RP-HPLC purification. Introduction of the 
acetic acid arm to obtain the BFC NODIA-Me 8 was accomplished by reductive amination using 
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glyoxylic acid as previously reported with an overall yield of 22%.5 This is a ~two-fold 
improvement over the initial two-step synthesis. The advantage of Route A is the cost-effective 
and straightforward access to the mono-protected TACN ring. However, the harsh reaction 
conditions for removal of the final tosyl group from 3 limit its use to acid resistant substituents. 
Future work will focus on the optimization of the final deprotection step and might result in a 
further improvement of the overall yield. 
 In order to circumvent the need for harsh deprotection conditions, another synthesis route 
was investigated as a possible alternative (Scheme 1B). In this case, the TACN ring was converted 
into its di-BOC protected derivative 5 using BOC-ON (2-(Boc-oxyimino)-2-phenylacetonitrile) 
according to the literature.18 The acidic acid residue was then introduced to the di-BOC protected 
TACN derivative 5 via nucleophilic substitution using ethylbromoacetate and potassium carbonate 
to give compound 6 in 91% yield. BOC protection resulted in formation of different isomers that 
were identified by NMR. Removal of the BOC protecting groups was accomplished by reaction 
with TFA in CH2Cl2 to provide the intermediate 7 in quantitative yield. Once again, the 
introduction of the methylimidazole residues was achieved by reductive amination using 1-methyl-
2-imidazolecarboxaldehyde and sodium triacetoxyborohydride. Hydrolysis of the ethyl ester was 
accomplished by refluxing in 6 M hydrochloric acid for 5 days to obtain NODIA-Me 8 in 85% 
yield. The overall yield for this 4-step synthesis was 68%, which marks a ~five-fold improvement 
compared to the initial synthesis. Furthermore, hydrolysis of the ethyl ester of 6 can alternatively 
be performed prior to the introduction of the imidazole substituents with no significant differences 
in overall yield. Simultaneous removal of the BOC groups and hydrolysis of the ethyl ester was 
achieved by refluxing compound 6 in 6 M hydrochloric acid followed by the introduction of the 
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imidazole substituents. This way, acid sensitive substituents can be introduced after preparation of 
the mono acetic acid derivative.  
 Overall, two novel synthetic routes for the preparation of the BFC NODIA-Me 8 with 
improved overall yields have been developed. While route A is appealing due to the cost-effective 
build-up of the TACN ring, its major drawback is the removal of the final toysl protecting group, 
which could only be achieved in relatively low yield resulting in a decrease of the overall yield. 
The harsh reaction conditions also limit this pathway to acid-resistant substituents. On the other 
hand, route B provided NODIA-Me 8 in a significantly improved overall yield and allows the 
introduction of acid-sensitive substituents for future applications. A minor drawback of route B is 
that this route does not include the preparation of the costly TACN macrocycle.  
 
111Indium radiolabeling and stability experiments  
The complex formation of the imidazole-type ligands NOTI-Me and NODIA-Me with the 
important PET isotope 68Ga3+ was recently described.5 We found that the borderline N donors of 
the imidazoles (according to Pearson’s HSAB principle) in combination with the TACN moiety 
are well suited for complexation of the hard Lewis acid Ga3+. Motivated by these results, we were 
also interested in the complex formation of NODIA-Me with nat/111In3+ as this might further expand 
the applicability of our chelating system for radiopharmaceutical development. 
 The most important requirement for a BFC is its ability to complex the radiometal of interest. 
Labeling properties of the model chelator NODIA-Me-NH-Et 12, in which the acetic acid was 
transformed into the corresponding ethylamide to mimic conjugation to a targeting vector, as well 
as the PSMA-targeting bioconjugate 13 with the gamma-emitter 111In3+ were therefore studied in 
detail (Scheme 3). In order to determine the optimal labeling conditions in terms of molar activity, 
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time, temperature and pH, initial experiments were performed with the model compound NODIA-
Me-NH-Et 12. First, the minimum amount of 12 to achieve quantitative radiochemical conversion 
(RCC) at pH 5.5 in acetate buffer at r.t. and 95 °C was determined. These conditions have been 
successfully applied for 111In-labeling of other BFCs such as DPTA, DOTA and NOTA.19-22 As 
can be seen form the results given in Figure 1A, a chelator concentration of 0.4 µM was necessary 
to obtain quantitative RCCs at r.t., which corresponded to a molar activity of Am = ~30 MBq nmol-
1. With decreasing ligand concentrations, the RCC decreased subsequently at ambient temperature. 
However, heating to 95 °C resulted in quantitative RCCs at ligand concentrations as low as 0.05 
µM corresponding to a molar activity of Am = ~240 MBq nmol-1. Next, the effect of the pH on the 
RCC of NODIA-Me-NH-Et 12 (Figure 1B) was studied. With the exception of pH 4.0, quantitative 
RCCs were obtained over a pH range of 5.5 to 8.2 at r.t. and 95 °C using a ligand concentration of 
0.4 µM.  
 Since the presence of a targeting vector can have an impact on the radiolabeling properties, 
additional labeling experiments using the PSMA-targeting bioconjugate 13 were performed. First, 
the optimal pH for radiolabeling of the PSMA-conjugate 13 was determined at a conjugate 
concentration of 0.33 µM. At 95 °C, quantitative RCCs in molar activities of ~30 MBq nmol-1 
were obtained over the entire investigated pH range from 4.0 to 8.2 (Figure 1C). To the contrary, 
significant differences in RCC were found at r.t. Similar to the ligand 12, the optimal pH for 
radiolabeling of the bioconjugate 13 was pH 5.5 but the RCC decreased significantly at r.t. at pH 
values below and above pH 5.5. Interestingly, the nature of the buffer salt (sodium acetate versus 
MES) did not impact the RCC at pH 5.5, while at pH 8.2 the difference in RCCs between HEPES 
and sodium acetate was ~25%.  
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 Besides the labeling efficiency, the stability/inertness of the radiometal complex is of 
importance for radiopharmaceutical applications. Hence, the stability of 111In-labeled 13 was 
assessed in ligand challenge and serum stability measurements. For the ligand exchange study, an 
aliquot of [111In]In-13 was incubated in ~3×106-fold molar excess of DTPA at r.t. and samples 
were analyzed at selected time points by RP-HPLC. Corresponding chromatographic data is given 
in the Supporting Information. No exchange was noted for up to 24 h confirming the formation of 
a stable [111In]In-13 complex under these conditions. This finding was furthermore corroborated 
by serum stability measurements, in which [111In]In-13 remained intact to >99% for up to 24 h 
underscoring the stability of the radiometal complex. The protein bound fraction of [111In]In-13 
was with 30.3 ± 3.9% comparable to that of previously reported conjugates [64Cu]Cu-13, 
[68Ga]Ga-13 and [68Ga]Ga-PSMA-HBED-CC.6 The octanol/PBS partition coefficient log Doct/PBS 
of [111In]In-13 was determined to -3.57 ± 0.01 making it slightly more lipophilic than its 64Cu- and 
68Ga-labeled counterparts with log Doct/PBS values of -3.99 ± 0.05 and -4.27 ± 0.08, respectively.6    
 
Complex formation of NODIA-Me-NH-Et with In3+ 
To better understand the encouraging results of the labeling and stability experiments, the complex 
formation of NODIA-Me-NH-Et 12 with natIn3+ was investigated. To gain further insights into the 
structural features of corresponding metal complexes, a series of 1D- and 2D-NMR measurements 
of In-12 were performed in aqueous medium. Figure 2 shows a comparison between the proton 
NMR spectra of metal-free 12 and In-12. A detailed overview of the proton and carbon NMR 
resonances is given in the Supporting Information. In these NMR studies, a similar trend was 
observed as seen for the previously described Ga(NODIA-Me-NH-Me) complex.5 Upon metal 
coordination, the proton resonances of the TACN macrocycle are deshielded compared to the free 
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ligand confirming coordination to the metal center. The diastereotopic ring protons of TACN 
exhibit an AA’BB’ multiplet confirming a slow TACN ring conformational interconversion for 
In-12 comparable to the In(NOTA) complex.23 Similar to studies on Ga(NODIA-Me-NH-Me), the 
imidazole protons are shifted to higher field, which is caused by the anisotropic effect of the 
aromatic imidazole rings. The protons of the CH2 groups of the methylimidazole arms are not 
chemically equivalent and hence show an AB coupling pattern, which is consistent with an inert 
binding of the imidazole N donors to the metal center. In contrast, the methylene protons of the 
acetic acid arms of In(NOTA) resonated as singlets being representative for a short lifetime of 
corresponding In-O bonds.23 The CH2 protons of the acetic acid arm show a singlet indicating that 
the amide function is most likely not involved in metal binding. However, from these results a fast 
exchanging coordination via the carbonyl-O or amide-NH in solution cannot entirely be excluded. 
Interestingly, corresponding protons are also shielded, which is in contrast to the Ga(NODIA-Me-
NH-Me) complex. Altogether, the proton NMR of In-12 is consistent with formation of a rigid 1:1 
chelate with a slow conformational interconversion of the macrocycle and inert In-N bonds to the 
imidazole arms.  
 Trivalent indium ions can form complexes with coordination numbers four to eight and the 
majority of ligands used for radiopharmaceuticals form six-, seven- and eight-coordinate 
complexes.12 For TACN derived ligands coordination numbers 6 and 7 have been reported. For 
example, X-ray analysis of In(NOTA) showed formation of a heptacoordinate complex with a 
pentagonal bipyramidal geometry with the coordination sphere being formed by six donor atoms 
provided by NOTA and an additional coordinated chloride anion.23 However, in aqueous solution 
NMR spectral data suggested a time-averaged six-coordinate C3 symmetric In(NOTA) complex.24 
X-ray analysis of structurally related In-(R,R,R)-1,4,7-tris(2′-methylcarboxymethyl)-
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triazacyclononane complex revealed a distorted trigonal prismatic coordination sphere.25 Six-
coordinate In complexes have also been reported for a tris(phenylphosphinate)- as well as a 
tris(mercaptoethyl)-armed TACN derivative.26, 27 In case of In(NODIA-Me-NH-Et), formation of 
a seven- or even eight-coordinate complex with additional weakly bound monodentate ligands 
such as H2O, hydroxide or chloride, etc. cannot entirely be excluded even though coordination of 
such ligands could not be shown by NMR. Additional IR spectroscopy of 12 and In-12 to elucidate 
further the coordination environment of the chelate was not conclusive due to overlapping signals 
in the regions of interest. Mass spectrometry of In-12 and In-13 only showed m/z consistent of 
metal chelates without the presence of additional ligands. Moreover, an exchange between 
monodentate ligands, as reported by our group for a similar 68Ga-labeled NODIA-Me-Ahx-PSMA 
conjugate5, was not noted in any experiments of nat/111In-12 or nat/111In-13. From these data, it can 
be concluded that NODIA-Me forms an In complex of uniform composition. Chemically plausible 
is either a six-coordinate complex involving donation from the amide group, or a seven/eight-
coordinate complex with additional monodentate ligands, most likely H2O molecules.  
 
Competitive binding assay 
To demonstrate the applicability of the In(NODIA-Me) complex for biological applications, 
preliminary biological testing was performed using the bioconjugate 13. Corresponding 64Cu- and 
68Ga-labeled NODIA-Me-NaI-Ahx-PSMA conjugates were recently evaluated by our group.6 For 
comparison and to study the influence of the indium complex on biological properties, the binding 
affinities of 13 and In-13 were determined in competitive binding assays on PSMA-positive 
LNCaP cells as previously described.6 A graphical representation of corresponding IC50 curves is 
given in Figure 3. Coordination of the In3+ cation resulted in a ten-fold decrease in affinity versus 
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the metal-free conjugate 13 with IC50 values of 2539 ± 100 nM and 233 ± 10 nM, respectively. 
IC50 values of the previously reported counterparts Cu-13 and Ga-13 were determined to 681 ± 7 
nM and 176 ± 10 nM, respectively. The BFC NODIA-Me 8 does not possess any charge 
compensating donor atoms resulting in metal complexes with a positive overall charge. Since both 
conjugates form complexes with two-fold positive overall charge, in case of the Ga complex either 
a hydroxide or chloride anion occupy the remaining coordination site, we attributed the lower 
affinity of Cu-13 versus Ga-13 to differences in complex size and polarity. The In3+ cation is 
sterically more demanding due to its larger ionic radius compared to Cu2+ and Ga3+ making the 
corresponding complex obviously too bulky for optimal binding to PSMA. Overall, the results of 
the competitive cell binding assay did not justify testing of [111In]In-13 in animals. 
 
Conclusions 
In this work, two novel synthesis strategies for NODIA-Me were introduced. In both cases using 
different protection/deprotection techniques, the overall yield was improved. While one synthetic 
route provided cost-effective and straightforward access to the mono-protected TACN ring, the 
relatively low yield for the removal of the final tosyl protecting group resulted only in a two-fold 
increase in overall yield. In addition, the harsh deprotecting conditions required for the removal of 
the final tosyl group limits the application of this route to acid resistant substituents. Via the second 
strategy using BOC protecting groups, the overall yield was significantly improved five-fold 
allowing the preparation of NODIA-Me in multi-gram scale. Importantly, this pathway is also 
compatible with the introduction of acid-sensitive substituents for future applications. Both 
pathways avoid the cumbersome and time-consuming purification by RP-HPLC. 
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 In the second part of this work, preliminary studies on the complex formation of NODIA-
Me with nat/111In were performed. The BFC NODIA-Me was successfully labeled with the gamma-
emitter 111In at ambient temperature in high radiochemical yield and purity as well as moderate to 
high molar activities. Furthermore, the corresponding 111In complex was highly stable in vitro as 
shown by human serum stability and ligand challenge experiments. The model compound NODIA-
Me-NH-Et forms rigid 1:1 chelates with In3+, which is in accordance with our previous report on 
a similar complex of its group 13 congener Ga3+. The indium-labeled NODIA-Me-NaI-Ahx-
PSMA bioconjugate was also tested in competitive cell binding experiments. In comparison to the 
copper- and gallium-labeled counterparts, the binding affinity was very low being a consequence 
of the rather bulky indium complex, which obviously avoids optimal accommodation of the In-
labeled bioconjugate to PSMA. Summarizing, the BFC NODIA-Me is now accessible in large 
scale. The results of 111In-labelling and in vitro stability experiments are encouraging and support 
future development of 111In-labeled radiopharmaceuticals based on our chelating system for 
evaluation with more appropriate targeting vectors in vivo. 
  
 Page 26 
 
Acknowledgements 
JPH thanks the Department of Nuclear Medicine, University Hospital Freiburg, the German 
Cancer Consortium (DKTK), the German Cancer Research Center (DKFZ), the Swiss Cancer 
League (Krebsliga Schweiz; KLS-4257-08-2017), the Swiss National Science Foundation (SNSF 
Professorship PP00P2_163683), the European Research Council (ERC-StG-2015, NanoSCAN – 
676904), and the University of Zurich for financial support. MDB thanks the Chemistry 
Department of the Albert-Ludwigs-University Freiburg (Germany) for its support, in particular 
Christoph Warth for MS measurements. MDB also thanks the Fonds der Chemischen Industrie for 
funding.  
 
 
  
 Page 27 
 
References  
1. B. M. Zeglis, J. L. Houghton, M. J. Evans, N. Viola-Villegas and J. S. Lewis, Inorg. Chem., 
2014, 53, 1880-1899. 
2. M. D. Bartholomä, Inorg. Chim. Acta, 2012, 389, 36-51. 
3. C. Gotzmann, F. Braun and M. D. Bartholomä, RSC Advances, 2016, 6, 119-131. 
4. M. Le Fur, M. Beyler, N. Le Poul, L. M. Lima, Y. Le Mest, R. Delgado, C. Platas-Iglesias, V. 
Patinec and R. Tripier, Dalton Trans., 2016, 45, 7406-7420. 
5. A. Schmidtke, T. Läppchen, C. Weinmann, L. Bier-Schorr, M. Keller, Y. Kiefer, J. P. Holland 
and M. D. Bartholomä, Inorg. Chem., 2017, 56, 9097-9110. 
6. T. Läppchen, J. P. Holland, Y. Kiefer and M. D. Bartholomä, EJNMMI Radiopharm. Chem., 
2018, 3, 6. 
7. S. S. Taneja, Reviews in Urology, 2004, 6, S19-S28. 
8. T. M. O'Dorisio and L. B. Anthony, Front. Horm. Res., 2015, 44, 177-192. 
9. W. H. Simon and W. S. Joseph, Clin. Podiatr. Med. Surg., 1988, 5, 329-340. 
10. P. J. Jeffery, S. Sostre, L. R. Scherer, W. Kasecamp and E. E. Camargo, Eur. J. Nucl. Med., 
1990, 17, 365-368. 
11. S. S. Taneja, Rev. Urol., 2004, 6 Suppl 10, S19-28. 
12. T. J. Wadas, E. H. Wong, G. R. Weisman and C. J. Anderson, Chem. Rev., 2010, 110, 2858-
2902. 
13. S. Liu, Adv Drug Deliv Rev, 2008, 60, 1347-1370. 
14. H. E. Gottlieb, V. Kotlyar and A. Nudelman, J. Org. Chem., 1997, 62, 7512-7515. 
15. P. Zanzonico, J. Nucl. Med., 2009, 49, 1114-1131. 
16. M. Benešová, U. Bauder-Wüst, M. Schäfer, K. D. Klika, W. Mier, U. Haberkorn, K. Kopka 
and M. Eder, J. Med. Chem., 2016, 59, 1761-1775. 
17. D. A. Valyaev, S. Clair, L. Patrone, M. Abel, L. Porte, O. Chuzel and J.-L. Parrain, Chemical 
Science, 2013, 4, 2815-2821. 
18. H. S. Chong, X. Ma, T. Le, B. Kwamena, D. E. Milenic, E. D. Brady, H. A. Song and M. W. 
Brechbiel, J. Med. Chem., 2008, 51, 118-125. 
19. Z. Varasteh, I. Velikyan, G. Lindeberg, J. Sörensen, M. Larhed, M. Sandström, R. K. 
Selvaraju, J. Malmberg, V. Tolmachev and A. Orlova, Bioconjugate Chem., 2013, 24, 1144-
1153. 
20. K. G. Andersson, M. Rosestedt, Z. Varasteh, M. Malm, M. Sandstrom, V. Tolmachev, J. 
Lofblom, S. Stahl and A. Orlova, Oncol. Rep., 2015, 34, 1042-1048. 
21. J. Malmberg, A. Perols, Z. Varasteh, M. Altai, A. Braun, M. Sandstrom, U. Garske, V. 
Tolmachev, A. Orlova and A. E. Karlstrom, Eur. J. Nucl. Med. Mol. Imaging, 2012, 39, 481-
492. 
22. M. Brom, L. Joosten, W. J. G. Oyen, M. Gotthardt and O. C. Boerman, EJNMMI Research, 
2012, 2, 4-4. 
23. C. J. Broan, J. P. L. Cox, A. S. Craig, R. Kataky, D. Parker, A. Harrison, A. M. Randall and 
G. Ferguson, J. Chem. Soc. Perk. 2, 1991, DOI: 10.1039/P29910000087, 87-99. 
24. A. S. Craig, I. M. Helps, D. Parker, H. Adams, N. A. Bailey, M. G. Williams, J. M. A. Smith 
and G. Ferguson, Polyhedron, 1989, 8, 2481-2484. 
25. R. C. Matthews, D. Parker, G. Ferguson, B. Kaitner, A. Harrison and L. Royle, Polyhedron, 
1991, 10, 1951-1953. 
 Page 28 
 
26. E. Cole, R. C. B. Copley, J. A. K. Howard, D. Parker, G. Ferguson, J. F. Gallagher, B. Kaitner, 
A. Harrison and L. Royle, J Chem Soc Dalton, 1994, DOI: DOI 10.1039/dt9940001619, 1619-
1629. 
27. U. Bossek, D. Hanke, K. Wieghardt and B. Nuber, Polyhedron, 1993, 12, 1-5. 
 
 
 
 Page 29 
 
Figure, Scheme and Table Legends 
 
Scheme 1. Synthesis routes for the BFC NODIA-Me 8. Route A: i) Cs2CO3, DMF, 2 d, 96%; ii) 
phenol, HBr/AcOH, 3 d, 90 °C, 78%; iii) 1-methyl-2-imidazolecarboxaldehyde, NaBH(OAc)3, 
THF, 24 h, 98%; iv) H2SO4 conc., 110 °C, 48 h, 34%; v) glyoxylic acid, NaBH(OAc)3,1,2-
dichloroethane, 16 h, 90%. Route B: vi) BOC-ON, CHCl3, 3 d, 88%; vii) K2CO3, 
ethylbromoacetate, MeCN, reflux, 18 h, 91%; viii) CH2Cl2, TFA, 0 °C to r.t., 2.5 h, quantitative; 
ix) 1-methyl-2-imidazolecarboxaldehyde, DIPEA, NaBH(OAc)3, THF, 50 °C, 20 h; x) 6 M HClaq., 
reflux, 5 d, 85% over two steps  
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Scheme 2. Synthesis of model compound NODIA-Me-NH-Et 12. i) K2CO3, CH2Cl2, 17 h, 61%; 
ii) K2CO3, 5, MeCN, 18 h, 89%; iii) TFA, CH2Cl2, 2 h, 73%; iv) 1-methyl-2-
imidazolecarboxaldehyde, NaBH(OAc)3, THF, 22 h, 62% 
 
 
Scheme 3. Model compound NODIA-Me-NH-Et 12 and PSMA-targeting bioconjugate NODIA-
Me-NaI-Ahx-PSMA 13 
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Figure 1. 111In-labeling experiments at r.t. / 95 °C and various pHs (all buffers 0.1 M). A) NODIA-
Me-NH-Et 12 at various ligand concentrations at pH 5.5 (NaOAc 0.1 M); B) NODIA-Me-NH-Et 
12 at different pH values (c(L) = 0.4 µM); C) NODIA-Me-NaI-Ahx-PSMA 13 at different pH 
values (c(L) = 0.33 µM) 
 
 
Figure 2. Proton NMR spectra of (A) complex In-12 and (B) metal-free NODIA-Me-NH-Et 12  
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Figure 3. Determination of binding affinity of 13 and In-13 by competitive titration on LNCaP 
cells using [68Ga]Ga-PSMA-HBED-CC as radioligand 
 
 
